I-Diadem srl, inkampani eyenza ukuhlolwa okusekelwe egazini kokubikezela kusenesikhathi kanye nokuxilongwa kwesifo i-Alzheimer's (AD), namuhla imemezele ukuthi yethule imininingwane engqungqutheleni yezizwe ngezizwe ye-AD/PD™ 2022 ye-Alzheimer's and Parkinson's Diseases (AD/PD22) ekhombisa ukuthi Isivivinyo sayo esisha se-AlzoSure® Qinisekisa igazi singakhomba ngokunembile iziguli ezinesifo i-Alzheimer's. Isethulo esithi, “Ukuhlolwa Kokuqala Okusekelwe Egazini Okungahlaseli Kokuhlonza Isifo Se-Alzheimer kanye Nokunye Ukuwohloka Komqondo,” kwethulwe yisikhulu esiphezulu se-Diadem uPaul Kinnon engqungqutheleni eyayiseBarcelona, eSpain ngoMashi 19, 2022.
I-AlzoSure® Confirm iye yathuthukiswa endaweni efanayo yobuchwepheshe esekelwe ku-AlzoSure® Predict, ukuhlolwa kwegazi okubikezelwe kwe-Diadem okungabikezela ngokunembile ukuthi umuntu onezinguquko zangaphambi kwesikhathi zokuqonda uzodlulela ku-Alzheimer's kuze kube iminyaka eyisithupha ngaphambi kokuba isimo sibonakale ngokugcwele. I-AlzoSure® Predict ikhethwe njenge-Breakthrough Device yi-US Food & Drug Administration futhi muva nje ithole umaki we-CE-IVD oyivumela ukuthi imakethwe e-UK nase-European Union.
Ukuhlolwa okusha kusekelwe ku-biomarker efanayo ye-U-p53AZ ehlanganisayo-okuhlukile okuhambisanayo kwe-p53-okuye kwahlotshaniswa ne-pathogenesis ye-AD ezifundweni ezingaphezu kuka-400, nokusebenzisana okubhaliwe ne-amyloid, i-tau nezinye izici ezihlobene nokuqhubeka kweziguli. ku AD. Ubuchwepheshe obunelungelo lobunikazi be-Diadem buthuthukiswe kusetshenziswa inkundla yayo ye-U-p53AZ.
Ocwaningweni olwethulwe ku-AD/PD22, abacwaningi be-Diadem basebenzise isethi engaphansi yamasampula asuka kusizindalwazi sesikhathi eside seziguli ezicishe zibe ngu-500 ezibonisa izigaba ezihlukene zokuncipha kwengqondo ukuze kuphenywe ukulandelana okugcwele kokuguqulwa kwangemuva kokuhumusha (PTMs) kwe-U-p53AZ phakathi nesifundo. yokuqhubeka okuphetha ngesifo i-Alzheimer's. Bathole ukuthi “izigxivizo zeminwe” ezithile ze-PTM, noma amasiginesha, zaziyizimpawu zezigaba ezihlukene zokuqhubekela ku-AD. I-AlzoSure® Confirm isebenzisa isiginesha ye-PTM ebonisa isifo se-Alzheimer esigcwele ukuze inikeze ukuhlolwa kwe-biomarker esekwe egazini okungenzeka kukwazi ukuxilonga i-AD. Kudatha yokuqala yokuqinisekiswa komtholampilo i-Diadem ethulwa ku-AD/PD22, lesi siginesha ye-PTM ikwazile ukuthola ngokuthembekile iziguli ezine-AD futhi ukuzehlukanisa ezigulini ezinokunye ukuwohloka komqondo.
"Kwa-Diadem, sizibophezele ekuthuthukiseni ukuhlolwa kwegazi okufinyelelekayo nokuxilonga okukwazi ukuhlonza ngokunembile abantu abanesifo i-Alzheimer noma abazothuthukela ku-AD eminyakeni ezayo," kusho uMnu. Kinnon. “Ukuhlolwa kwethu kwegazi okubikezelwe kwe-AlzoSure® Predict sekuqinisekisiwe kakade ezifundweni ezinkulu zomtholampilo zesikhathi eside futhi kuzotholakala e-EU ngasekupheleni kwalo nyaka. Sijabule kakhulu futhi ngokuhlolwa kwethu okusha kwe-AlzoSure® Confirm, okunamandla okuxilonga ngokunembile nangokuqondile isifo i-Alzheimer's kusetshenziswa ukuhlolwa kwegazi okulula. Ukuntuleka kokuxilonga okufika ngesikhathi, okunembile nokuthengekayo kuye kwakhinyabeza inqubekelaphambili ekuthuthukiseni izindlela zokwelapha ezisebenza kahle kakhulu zeziguli ze-AD, futhi sibheke ngabomvu ukusebenzisana nozakwethu abahlukahlukene ukuze sikhiqize futhi sibike idatha eyengeziwe eqinisekisayo ku-AlzoSure® Confirm.”
LOKHO ONGAKUTHATHE KULESI SIHLOKO:
- In the study presented at AD/PD22, Diadem researchers used a subset of samples from a longitudinal database of almost 500 patients exhibiting different stages of cognitive decline to investigate the full sequence of post-translational modifications (PTMs) of U-p53AZ over the course of the continuum that culminates in Alzheimer’s disease.
- Diadem srl, a company developing blood-based tests for the early prediction and diagnosis of Alzheimer’s disease (AD), today announced that it presented data at the AD/PD™ 2022 International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD22) showing that its new AlzoSure® Confirm blood test can accurately identify patients with Alzheimer’s disease.
- AlzoSure® Confirm has been developed on the same technology platform that underlies AlzoSure® Predict, Diadem’s prognostic blood test that can accurately predict whether or not an individual with early cognitive changes will progress to Alzheimer’s disease up to six years before the condition is fully manifested.
